Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOSTON, Feb. 02, 2024 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (Nasdaq:PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that on February 1, 2024, the Compensation Committee of Praxis’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 1,600 shares of its common stock and restricted stock unit awards covering an aggregate of 1,450 shares of its common stock to two new non-executive employees under the Praxis Precision Medicines, Inc. 2024 Inducement Plan (the “2024 Inducement Plan”). The stock options and restricted stock units were granted as inducements material to the employees’ entering into employment with Praxis in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (PRAX)
- Praxis Precision Medicines Highlights DEE Clinical Program Updates at Virtual Investor Event
- Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2025 Financial Results
- Praxis Precision Medicines Provides Update on Essential3 and Corporate Update
- Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities
- Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome